CRADA pricing challenged

WASHINGTON - Members of an NIH advisory panel on Friday excoriated the reasonable pricing clause in the NIH model Cooperative Research and Development Agreement after hearing representatives of industry, academia and NIH describe the negative impact it has had on government-industry cooperation.

The panel members are consultants to the Advisory Committee to the NIH Director (ACD). The ACD meets twice annually and will consider the results of the deliberations when it meets again in September. A report based on the panel's discussions will

Read the full 835 word article

How to gain access

Continue reading with a
two-week free trial.